Presentation of “SPI2” Phase III Results at the EAN Virtual Congress 2020

MedDay Reports Top-Line Data from Phase III Trial “SPI2” for Treatment of Progressive Forms of Multiple Sclerosis

MedDay Reports Last Patient Study Visit in Second Phase 3 Clinical Trial with MD1003®, an Important Milestone Towards Completion of the SPI2 Study in Progressive Multiple Sclerosis